Bio-View Ltd (BIOV) - Total Liabilities

Latest as of June 2025: ILA8.26 Million ILA ≈ $22.13K USD

Based on the latest financial reports, Bio-View Ltd (BIOV) has total liabilities worth ILA8.26 Million ILA (≈ $22.13K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Bio-View Ltd to track the company's year-over-year net asset growth rate.

Bio-View Ltd - Total Liabilities Trend (2009–2024)

This chart illustrates how Bio-View Ltd's total liabilities have evolved over time, based on quarterly financial data. See Bio-View Ltd (BIOV) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Bio-View Ltd Competitors by Total Liabilities

The table below lists competitors of Bio-View Ltd ranked by their total liabilities.

Company Country Total Liabilities
Tek Seng Holdings Bhd
KLSE:7200
Malaysia RM49.08 Million
NEXTCHIP Co. Ltd
KQ:092600
Korea ₩21.52 Billion
Shenzhen Properties & Resources Development Group Ltd
SHE:200011
China HK$11.86 Billion
Agricore CS Holdings Berhad
KLSE:0309
Malaysia RM25.01 Million
Falcon Power Co Ltd
TW:1516
Taiwan NT$3.94 Million
Kisan Telecom Co. Ltd
KQ:035460
Korea ₩68.24 Billion
ReWalk Robotics Ltd
NASDAQ:LFWD
USA $27.13 Million
CLEAN TEQ WATER LTD
F:9NK
Germany €8.37 Million

Liability Composition Analysis (2009–2024)

This chart breaks down Bio-View Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bio-View Ltd (BIOV) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.29 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Bio-View Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Bio-View Ltd (2009–2024)

The table below shows the annual total liabilities of Bio-View Ltd from 2009 to 2024.

Year Total Liabilities Change
2024-12-31 ILA10.68 Million
≈ $28.62K
-27.12%
2023-12-31 ILA14.65 Million
≈ $39.28K
+7.31%
2022-12-31 ILA13.65 Million
≈ $36.60K
+6.18%
2021-12-31 ILA12.86 Million
≈ $34.47K
+45.77%
2020-12-31 ILA8.82 Million
≈ $23.65K
-26.70%
2019-12-31 ILA12.03 Million
≈ $32.26K
+12.88%
2018-12-31 ILA10.66 Million
≈ $28.58K
-5.30%
2017-12-31 ILA11.26 Million
≈ $30.18K
+1.39%
2016-12-31 ILA11.10 Million
≈ $29.77K
+6.85%
2015-12-31 ILA10.39 Million
≈ $27.86K
-19.72%
2014-12-31 ILA12.94 Million
≈ $34.70K
+6.16%
2013-12-31 ILA12.19 Million
≈ $32.69K
-7.14%
2012-12-31 ILA13.13 Million
≈ $35.20K
-8.26%
2011-12-31 ILA14.31 Million
≈ $38.37K
+7.74%
2010-12-31 ILA13.29 Million
≈ $35.62K
+1.23%
2009-12-31 ILA13.12 Million
≈ $35.18K
--

About Bio-View Ltd

TA:BIOV Israel Medical Devices
Market Cap
$31.07 Million
ILA11.59 Billion ILA
Market Cap Rank
#25034 Global
#361 in Israel
Share Price
ILA89.50
Change (1 day)
-4.69%
52-Week Range
ILA11.90 - ILA131.90
All Time High
ILA5076.00
About

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more